[Skip to Content]
Access to paid content on this site is currently suspended due to excessive activity being detected from your IP address Please contact the publisher to request reinstatement.
[Skip to Content Landing]
Views 5,072
Citations 0
Biotech Innovations
July 9, 2019

Patient Receives First Genetically Engineered Phage Treatment

JAMA. 2019;322(2):107. doi:10.1001/jama.2019.9394

A pediatric patient with cystic fibrosis and a double-lung transplant received a genetically engineered 3-phage cocktail to treat a life-threatening antibiotic-resistant Mycobacterium abscessus infection for which all standard therapeutic options had been exhausted. Over 7 months of twice-daily intravenous infusions, as well as daily topical phage therapy, the 15-year-old patient’s surgical wound and skin lesions healed gradually and her lung and liver function improved. No adverse reactions to the treatment were reported.